GlassScriptPhysician profile
Aaron Michael Carter
NPI 1528247806
$7,717.12
in general payments reported to CMS, 2019-2025
33 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $514 · 2021: $549 · 2022: $451 · 2023: $2,302 · 2024: $2,017 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,391 · Travel and Lodging: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.40 |
| Travel and Lodging | $1,743.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,607.64 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Curonix LLC | $1,320.03 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic USA, INC. | $873.10 | 2019-2020 | |
| Spr Therapeutics, INC | $754.21 | 2024 | Sprint Pns System |
| Boston Scientific Corporation | $588.57 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Saluda Medical Americas, INC. | $416.66 | 2023-2024 | Evoke Scs, Evoke |
| Si-Bone, INC. | $411.67 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $382.14 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Forte Bio-Pharma LLC | $164.68 | 2019-2025 | Prolate, Tanlor, Nalocet |
| Scilex Pharmaceuticals INC. | $162.39 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.14 | 2019-2021 | |
| Painteq LLC | $108.28 | 2024 | Painteq |
| Pfizer INC. | $90.79 | 2019-2021 | |
| Redhill Biopharma INC. | $84.91 | 2020-2022 | |
| Nevro Corp. | $72.18 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $60.76 | 2019-2021 | |
| Abbott Laboratories | $60.40 | 2020-2025 | Proclaim, Eterna |
| Virtus Pharmaceuticals LLC | $51.85 | 2023-2024 | Levorphanol Tartrate |
| Almatica Pharma LLC | $48.20 | 2020 | |
| Biotronik Nro, INC. | $40.96 | 2025 | Prospera |
| Stryker Corporation | $35.40 | 2025 | Mild Device Kit, Optablate |
| Sentynl Therapeutics, INC. | $32.71 | 2019 | |
| Grt US Holding, INC. | $32.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.55 | 2020 | |
| Abbvie INC. | $27.09 | 2024 | |
| Fidia Pharma USA INC. | $21.90 | 2019 | |
| Tersera Therapeutics LLC | $20.67 | 2025 | Prialt |
| Vertex Pharmaceuticals Incorporated | $20.27 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.02 | 2023 | Horizant |
| Daiichi Sankyo INC. | $19.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.06 | 2019 | |
| Bausch Health US, LLC | $16.00 | 2019 | |
| Protega Pharmaceutials INC | $15.50 | 2024 | Roxybond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.